Abstract
There is a strong need for new antimitotic drugs that overcome the limitations of the currently used antitubulin compounds, mainly neurotoxicity and the development of resistance. One of the most promising new targets is kinesin spindle protein (KSP, also known as Eg5), which contributes to the formation of mitotic spindle during cell division and has not been reported to play any other cellular role so far. This review covers KSP inhibitors binding at the allosteric, induced-fit L5 site reported between 2008 and December 2013. Among them, main groups include dihydropyrimidines, STLC derivatives, quinazoline-based compounds and pyrrole/ pyrazole and related agents. Structure-activity relationships are described, as well as the synthesis of representative compounds. They are remarkably selective for KSP and produce G2/M mitotic arrest accompanied by a characteristic monoastral cellular phenotype. Some of them have entered clinical trials, the most advanced being in Phase II. Therefore, KSP inhibitors show great potential as future clinical antimitotic agents, especially due to their activity in taxane-resistant tumors.
Keywords: Antimitotic, Antitumor, Inhibitors, Kinesin spindle protein, Structure-activity relationships, Synthesis.
Current Topics in Medicinal Chemistry
Title:KSP Inhibitors as Antimitotic Agents
Volume: 14 Issue: 20
Author(s): Concepcion Perez-Melero
Affiliation:
Keywords: Antimitotic, Antitumor, Inhibitors, Kinesin spindle protein, Structure-activity relationships, Synthesis.
Abstract: There is a strong need for new antimitotic drugs that overcome the limitations of the currently used antitubulin compounds, mainly neurotoxicity and the development of resistance. One of the most promising new targets is kinesin spindle protein (KSP, also known as Eg5), which contributes to the formation of mitotic spindle during cell division and has not been reported to play any other cellular role so far. This review covers KSP inhibitors binding at the allosteric, induced-fit L5 site reported between 2008 and December 2013. Among them, main groups include dihydropyrimidines, STLC derivatives, quinazoline-based compounds and pyrrole/ pyrazole and related agents. Structure-activity relationships are described, as well as the synthesis of representative compounds. They are remarkably selective for KSP and produce G2/M mitotic arrest accompanied by a characteristic monoastral cellular phenotype. Some of them have entered clinical trials, the most advanced being in Phase II. Therefore, KSP inhibitors show great potential as future clinical antimitotic agents, especially due to their activity in taxane-resistant tumors.
Export Options
About this article
Cite this article as:
Perez-Melero Concepcion, KSP Inhibitors as Antimitotic Agents, Current Topics in Medicinal Chemistry 2014; 14 (20) . https://dx.doi.org/10.2174/1568026614666141130095532
DOI https://dx.doi.org/10.2174/1568026614666141130095532 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology G4 Aptamers: Trends in Structural Design
Mini-Reviews in Medicinal Chemistry Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals Network Pharmacology-based Prediction and Verification of Shikonin for Treating Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design QbD Approach For Anti-Cancer Drugs - A Review
Current Pharmaceutical Analysis Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Neurotrophins in the Lower Urinary Tract: Becoming of Age
Current Neuropharmacology Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets QSAR and the Prediction of T-Cell Epitopes
Current Proteomics Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics